ImmuSmol

ImmuSmol is specialized in developing antibodies directed against small molecules. Supported by public institutions including BPI, Conseil Régional Nouvelle Aquitaine, as well as by its Co-founder Associate – SCHIEVER, Immusmol is established in Bordeaux, France.
The ImmuSmol team is made up of around twenty talents with different backgrounds and application fields, bringing their expertise and experience to the company. ImmuSmol aims to become a natural choice for small molecule antibodies development, collaborating with a worldwide network of scientists.
ImmuSmol’s focus: validated tools for detecting small molecules
ImmuSmol stands for antibodies against small molecules. While traditional antibodies only recognize large molecules such as proteins, ImmuSmol designs and develops antibodies capable of targeting low molecular weight entities, below 900 Daltons, that can be used for conventional staining applications as well as in the scope of novel immunoassays development
Their products are fully compatible with existing antibody-based technologies, small molecule antibodies are opening a whole new set of possibilities in research diagnostic and therapeutic applications.

The prices are on request! Contact Us by e-mail info@sobekbio.com

Recombinant 2019-nCoV S Protein RBD (N439K, C-6His) DRA101

The add to cart button will appear once you select the values above

Specifications

size	50ug\|500ug\|1mg

Alias:

2019-nCov RBD Protein; 2019-nCoV Spike RBD Protein

Classification:

Immuno-Diagnostics Reagents

Product information:

Recombinant SARS-CoV-2 S protein RBD Protein is produced by our Mammalian expression system and the target gene encoding Arg319-Phe541 (N439K) is expressed with a 6His tag at the C-terminus.

Species:

SARS-CoV-2

Isotype:

Conjugate tag:

C-6His

Source:

Human Cells

Formula:

Supplied as a 0.2 μm filtered solution of PBS, pH 7.4

Molecular weight:

25.9kDa

Purity:

Animal ingredients:

None

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com